Kwality Pharmaceuticals sets Aug 25-31 book closure for AGM
Kwality Pharmaceuticals Ltd has scheduled its 43rd AGM for August 31, 2026, with a book closure period from August 25 to 31. The company detailed the e-voting timeline, cut-off dates for notice and voting eligibility, and key agenda items including director reappointments and cost auditor remuneration.
*this image is generated using AI for illustrative purposes only.
Kwality Pharmaceuticals has fixed the book closure period from August 25, 2026, to August 31, 2026, to determine shareholders eligible for its 43rd Annual General Meeting (AGM). The company will conduct the AGM via Video Conferencing (VC) or Other Audio Visual Means (OAVM) on August 31, 2026, at 12:00 noon. Shareholders holding equity shares as of the cut-off date of August 24, 2026, will be entitled to participate in electronic voting and receive dividend entitlements, if declared.
The Register of Members and Share Transfer Books will remain closed during this period pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. A separate cut-off date of July 31, 2026, was established earlier to determine shareholders eligible to receive the AGM notice. This procedural step ensures that only those holding shares on the specified record dates can exercise voting rights or claim benefits associated with the meeting.
Voting Timeline and Mechanism
Electronic voting will be facilitated through the National Securities Depository Limited (NSDL) platform in compliance with Regulation 44 of the SEBI (LODR) Regulations, 2015. The voting window opens at 09:00 A.M. on August 28, 2026, and closes at 5:00 P.M. on August 30, 2026. Rishi Mittal has been appointed as the Scrutinizer for the e-voting process to ensure transparency and compliance with regulatory standards.
| Event | Date | Purpose |
|---|---|---|
| Notice Cut-off Date | July 31, 2026 | Determining shareholders for sending notice |
| E-Voting Start Date | August 28, 2026 | Electronic voting begins |
| Book Closure Start | August 25, 2026 | Register of Members closed |
| E-Voting End Date | August 30, 2026 | Electronic voting ends |
| Book Closure End / AGM | August 31, 2026 | AGM held via VC/OAVM |
Key Agenda Items
Shareholders will vote on several governance resolutions approved by the Board during its meeting on August 8, 2026. The Board also approved the financial results for FY26 under Section 134 of the Companies Act, 2013. Key items requiring shareholder ratification include:
- Reappointment of Whole Time Director: Aditya Arora is proposed for reappointment as Whole Time Director for five consecutive years, from September 30, 2026, to September 29, 2031. He oversees production, quality assurance, and regulatory filings.
- Regularization of Independent Director: Swanith Kapoor, initially appointed as an Additional Director (Independent) on June 2, 2026, seeks regularization for a five-year term ending May 31, 2031.
- Retiring Directors: Aditya Arora and Anju Arora are retiring by rotation under Section 152(6) of the Companies Act, 2013, and have offered themselves for reappointment.
- Cost Auditor Remuneration: M/s Verma Khushwinder & Co. Cost Accountants (FRN: 000469) were appointed as Cost Auditors for FY27. Their remuneration requires shareholder ratification.
The disclosure was made pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, and SEBI Master Circular HO/49/14/14(7)2025-FD POD2/I/3762/2026 dated January 30, 2026.
Historical Stock Returns for Kwality Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.52% | +2.60% | -1.53% | +57.09% | +57.09% | +57.09% |
How might the reappointment of Aditya Arora as Whole Time Director influence Kwality Pharmaceuticals' production efficiency and regulatory compliance strategies over the next five years?
What impact could the regularization of Swanith Kapoor as an Independent Director have on the company's corporate governance standards and board decision-making dynamics?
Given the appointment of M/s Verma Khushwinder & Co. as Cost Auditors for FY27, what specific cost optimization or operational efficiency measures are shareholders likely to scrutinize in the upcoming financial year?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
